Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05765357
Other study ID # ZDTQ-2017-QTZDK
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 16, 2017
Est. completion date October 27, 2017

Study information

Verified date April 2017
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Trastuzumab for injection is a biosimilar of Herceptin ® produced by Chia Tai Tianqing Biotechnology Co., LTD, which is a humanized IgG1 monoclonal antibody produced by chinese hamster ovary (CHO) cells. A randomized, double-blind, single-dose, parallel phase I study comparing trastuzumab for injection with Herceptin ® in healthy male volunteers was conducted to evaluate the similarities in pharmacokinetics, tolerability, safety and immunogenicity of Trastuzumab for injection and Herceptin®.


Recruitment information / eligibility

Status Completed
Enrollment 89
Est. completion date October 27, 2017
Est. primary completion date October 27, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Fully understand the purpose of the trial, and have a basic understanding of the pharmacological effects and possible adverse reactions of the drug under study; Voluntary written informed consent in accordance with the Helsinki Declaration; - Healthy male subjects aged = 18 years and = 65 years; - Body weight = 50 kg = 90 kg, body mass index = 18 = 28kg/m2; - The system examination indicators were within the normal range, or the examination results were abnormal but the researchers judged that there was no clinical significance; - Subjects agree to use reliable contraceptive methods for both themselves and their partners during the study period and for 6 months after the study drug infusion. Exclusion Criteria: - History of hypertension or abnormal blood pressure at screening/baseline measurement; - A history of albuminuria or albuminuria as assessed by the investigator as clinically significant; - Received any antibody or protein targeting Vascular Endothelial Cell Growth Factor (VEGF) or VEGF receptors in the previous 1 year; - Study the use of any biological product or live virus vaccine within 3 months prior to drug infusion, or the use of any monoclonal antibody within 12 months; - Have an inherited tendency to bleed or have coagulation dysfunction, or have a history of thrombosis or bleeding; - History of digestive tract perforation or digestive tract fistula; - Unhealed wound ulcers or fractures, or major surgery within 2 months prior to randomization or expected to be performed during the study period or within 2 months after study completion; - Use of a prescription or over-the-counter drug or nutritional supplement within the 5 half-life of the drug or nutritional supplement or within 2 weeks prior to the study drug use; - Positive virology test; - Known allergy to trastuzumab; - Known history of allergic diseases or allergic constitution; - Study the history of blood donation 3 months before drug infusion; - Received any other investigational drug therapy or participated in another interventional clinical trial within 2 months prior to screening - A history of alcohol or drug abuse in the 12 months prior to screening; - A history of mental illness; - Subjects whose spouses plan to become pregnant; - The study cannot be completed according to protocol requirements during the study period; - Conditions considered unsuitable for inclusion by other researchers.

Study Design


Intervention

Drug:
Trastuzumab for injection
Trastuzumab for injection manufactured by Chia Tai Tianqing. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
Herceptin
Herceptin is the brand name of Trastuzumab for injection manufactured by Roche. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.

Locations

Country Name City State
China Affiliated Hospital of Changchun University of Traditional Chinese Medicine Changchun Jilin

Sponsors (1)

Lead Sponsor Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area under drug concentration - time curve (AUC0-t) Area under the curve from time zero to the lowest detectable blood drug concentration Within 30 minutes before administration to 1344 hours after administration
Secondary Area under drug concentration - time curve (AUC0-8) The area under the curve extrapolating from time zero to infinity Within 30 minutes before administration to 1344 hours after administration
Secondary Peak concentration (Cmax) Peak maximum plasma drug concentration Within 30 minutes before administration to 1344 hours after administration
Secondary Time to reach maximum plasma (Tmax) Time to reach maximum plasma concentration after dosing Within 30 minutes before administration to 1344 hours after administration
Secondary Clearance (CL) Percentage of the body that eliminates organ-scavenging drugs Within 30 minutes before administration to 1344 hours after administration
Secondary half-life (T1/2) The time it takes for serum drug concentrations to drop by half Within 30 minutes before administration to 1344 hours after administration
Secondary Apparent volume of distribution (Vd/F) Apparent volume of distribution after administration Within 30 minutes before administration to 1344 hours after administration
See also
  Status Clinical Trial Phase
Withdrawn NCT04872608 - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Phase 1
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Completed NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Phase 1
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2